The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Skin, hair & anti-aging

Klow Blend

The Glow stack with added KPV: BPC-157, TB-500, GHK-Cu plus the anti-inflammatory K component.

2 min read 20 sources

To the product To the calculator
Still from the explainer video about this entry
No study of its own · not approvedLab tested in the shop

No time to read it all? The video sums up the whole entry in about a minute, from how it works to the studies and storage.

Summary

At a glance

Sources checked on 26 Oct 2026

On the blend itself
0 studies

neither in the trial registry nor in PubMed, as of 26 Oct 202618

BPC-157 studies in animals or cells
35 of 36

systematic review, only one study in humans3

All BPC-157 human studies
30 people

three small studies combined, very low certainty2

Wound closure in rats
+61 %

thymosin beta-4 at day 7 versus saline7

GHK-Cu
4,000 genes

at least this many human genes up- or downregulated (gene data)13

  • The Klow Blend is a ready-made mix of four peptides: BPC-157, TB-500, GHK-Cu and KPV. The K in the name stands for KPV.
  • There is not a single study on the blend itself, neither in the trial registry nor in PubMed. Everything here comes from studies on single components.1819
  • The only study testing two of the four components together (BPC-157 plus TB-500, tendon healing in rats) found no added benefit over either compound alone.1
  • The components have mainly been studied in animals and cells. For BPC-157, 35 of 36 studies in a systematic review were preclinical; all human studies combined cover 30 people.32
  • None of the four compounds is approved (as of October 2026). Everything here is the state of research, not a recommendation.204
Profile

Updated May 2026

Class
Healing/beauty blend

extended

Use
Subcutaneous

in mg

Contents
BPC-157 + TB-500 + GHK-Cu + KPV
WADA
Banned

peptides

Sizes
80 mg

1 size in the shop

Contents 16 sections
  1. At a glance
  2. What is the Klow Blend?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Dosing
  7. Injection
  8. What the research shows
  9. Research status
  10. On the skin
  11. Side effects
  12. Storage
  13. Related compounds
  14. FAQ
  15. Glossary
  16. Sources

What is the Klow Blend?

The Klow Blend is essentially the Glow stack plus KPV, hence the K in the name. It contains BPC-157, TB-500 and GHK-Cu for healing and skin plus KPV as an anti-inflammatory component, in an 80mg vial. You also find all four compounds individually in the lexicon.

Comparison

Two, three or four compounds

Which compounds each blend contains, as stated in the TPD lexicon. Tap a card to open its entry.

2 compounds BPC + TB Blend BPC-157 TB-500 GHK-Cu KPV 2 of 4 compounds 3 compounds Glow Blend BPC-157 TB-500 GHK-Cu KPV 3 of 4 compounds 3 compounds BPC + TB + KPV Blend BPC-157 TB-500 GHK-Cu KPV 3 of 4 compounds
4 compounds Klow Blend BPC-157 TB-500 GHK-Cu KPV 4 of 4 compounds

Simplified: more compounds in one vial does not automatically mean better. There is no study on the blend itself. 18

How it works

BPC-157 and TB-500 drive repair and cell migration, GHK-Cu promotes collagen and skin, KPV adds an anti-inflammatory action. So the Klow Blend covers repair, skin appearance and inflammation dampening in one.

The individual mechanisms are in the lexicon entries for BPC-157, TB-500, GHK-Cu and KPV.

Where it acts

Components and where they act

Tap a point or a card. Colour = component, data from studies on the single compound.

  1. Skin and wounds

    Wounds closed faster in rats, with more collagen and new vessels (thymosin beta-4)7

    TB-500
  2. Gut

    Gut inflammation reduced in two mouse colitis models, uptake via the transporter PepT115

    KPV
  3. Liver

    Tissue repair also described for liver, bone and stomach lining according to a review12

    GHK-Cu
  4. Heart

    After infarction in mice more heart muscle cells survived and heart function was better (thymosin beta-4)8

    TB-500
Glass skin layers above collagen fibres with a reddish glowing spot, blue molecules above them, one with a copper-coloured atom
Repair, collagen and calming of inflammation from four components. Symbolic image.

What you need

Supplies

2 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

Klow Blend vial and bacteriostatic water at the same size with the black TPD label, next to two U-100 insulin syringes, two alcohol swabs and a sharps container with a blue lid

  1. Klow Blend vial

    The Klow vial (lyophilized powder, four compounds).

    In the shop

  2. BAC water, syringes and swabs

    Bacteriostatic water, U-100 insulin syringes, alcohol swabs.

    In the shop Amazon (opens a new tab)

As an Amazon associate we earn from qualifying purchases. Links open Amazon - no extra cost for you.

Reconstitution

Use the peptide calculator. The values refer to the total amount. An 80mg vial with 3ml water gives roughly 27mg per ml. Just add the water to the vial and let it dissolve.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 80 mg + 3 ml = 26.67 mg/ml

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

Injection

The injection is subcutaneous, into the fat layer under the skin. Common spots are the abdomen (keep about two finger-widths clear of the navel), the front and the inner side of the thigh, or the back of the upper arm.

The short version:

Injection

Where and at what angle

Pick a spot or switch the angle. Subcutaneous means: into the fat layer, not the muscle.

Rotate the spot each time, never the same one twice in a row.

90°More fat under the skin

Rule of thumb: where there is more fat under the skin, insert straight at 90 degrees. In lean people with little fat, 45 degrees, so the needle stays in the fat layer. Simplified diagram.

  1. Clean the spot with an alcohol swab and let it dry

  2. Pinch up a small fold of skin

  3. Insert the needle: at 90 degrees where there is more fat under the skin, at 45 degrees in lean people with little fat

  4. Inject slowly, wait a moment, then withdraw

  5. Put the needle straight into the sharps container

Rotate the site each time so the tissue does not get irritated. Never the same spot twice in a row.

What the research shows

The components are individually described preclinically (KPV anti-inflammation: Dalmasso, 2008). For the fixed quadruple combination in humans there are no controlled studies, the benefit derives from the complementary mechanisms.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Wound healing in rats with thymosin beta-47

More skin closure or wound contraction versus the saline control

Skin closure at day 47 Re-epithelialisation of a full-thickness wound
Thymosin beta-4 (rat) +42%
Skin closure at day 77 up to this value
Thymosin beta-4 (rat) +61%
Wound contraction at day 77 at least this value
Thymosin beta-4 (rat) +11%

Thymosin beta-4 was applied to the wound or into the abdominal cavity. TB-500 is derived from it. These values are not shown for TB-500 alone or for the blend.

Where the knowledge on BPC-157 comes from3

Share of the 36 studies in a systematic review (literature up to June 2024)

Systematic review3 35 preclinical, 1 clinical study
Animal and cell studies 97%
Human studies 3%

The only clinical paper in the review was a retrospective analysis of 12 people. The authors found no clinical safety data.

Row of test tubes, alternating between twisted skin-coloured tissue strands and clear twisted glass strands
The data come from studies on single components. Symbolic image.

Research status

Where the research stands

There is no study on the blend itself. Shown are registered trials on single components, given by injection or infusion. As of 26 Oct 2026. 17

  1. Preclinical Animal and cell studies on each component
  2. Phase 1 2 trials on components, 2 completed
  3. Phase 2 2 trials on components, 2 completed
  4. Phase 3 no registered trial
  5. Approval not yet
Not approved, neither the blend nor any component. ChEMBL lists BPC-157 with phase 1 and thymosin beta-4 with phase 3 (as eye drops) as the highest phase, each without an approval year.20
Show all 2 phase 2 trials on a timelineHide timeline 2 completed 0 running 0 with results
Phase 2

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 2 trials on safety and pharmacokinetics, not shown as bars.

On the skin

Two components have also been studied applied directly. In humans GHK-Cu was used as a gel on foot ulcers in diabetes; the wounds closed better than with a gel without active ingredient (Mulder 1994). Thymosin beta-4, the model for TB-500, sped up wound closure in rats as a solution put on the wound (Malinda 1999). There is no study of KPV on human skin, nor of the blend itself.

Hand touching a swirl of white cream on a light marble slab with water droplets and white flowers
Symbolic image.

Side effects

  • Generally well tolerated, mainly local reactions at the injection site.
  • Solid long-term human data are missing.

Storage

Before mixing the powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. After mixing, keep in the fridge (2 to 8 degrees), do not freeze. It stays good there for at least 4 to 6 months with barely any loss of potency, in practice considerably longer. Swirl or shake to mix, both are fine.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark

Robust, no fridge needed. Keeps for several months without trouble.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

At least 4 to 6 months with barely any loss of potency. The copper in GHK-Cu often makes the solution slightly blue, that is normal.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same compounds: all in the TPD lexicon.

Klow Blend
BPC-157 Component, single entry in the lexicon TB-500 (Thymosin Beta-4) Component, single entry in the lexicon GHK-Cu Component, single entry in the lexicon KPV Component, single entry in the lexicon Klow Blend 110 The same four compounds, larger vial Glow Blend Like Klow, just without KPV BPC + TB Blend BPC-157 plus TB-500 BPC + TB + KPV Blend Like Klow, just without GHK-Cu GHK-Cu + KPV Blend GHK-Cu plus KPV

FAQ

Common questions about Klow Blend

Short answers, each backed by the sources below.

Are there studies on the Klow Blend?

No. As of 25 October 2026 there is no study on the ready-made blend, neither on ClinicalTrials.gov nor in PubMed. Only the single components have been studied, almost always each on its own. The only paper testing two components together (BPC-157 plus TB-500 in rats) found no added benefit of the combination.18191

What is in the Klow Blend?

Four peptides in one vial. BPC-157 comes from a protective protein in gastric juice, TB-500 is derived from thymosin beta-4, a protein that binds actin. GHK-Cu is a copper tripeptide found in the blood. KPV is a tripeptide from the hormone alpha-MSH. You also find all four individually in the lexicon.4101316

Is the combination stronger than the single compounds?

That has not been studied. The idea behind the blend is that the pathways complement each other. In the only study with two components together (tendon healing in rats), BPC-157 plus TB-500 gave no advantage over either compound alone. The authors suspect that both act on shared pathways.1

How well has BPC-157 been studied in humans?

Barely. A systematic review found 36 studies: 35 in animals or cells and one retrospective analysis of 12 people with knee pain. A second review from 2026 counted three small human studies with 30 people in total and rated the evidence as very low. Many animal studies come from a few research groups.325

Is TB-500 the same as thymosin beta-4?

Not quite. TB-500 is described as a fragment of thymosin beta-4. Most studies, including the wound healing in rats and the phase 1 trial into a vein, used full thymosin beta-4. As eye drops thymosin beta-4 reached phase 3, which is a different use. The registry lists no trial on TB-500 itself.117917

What is known about GHK-Cu and KPV?

According to gene data GHK-Cu regulates at least 4,000 human genes and promotes collagen and elastin in cell studies. In humans it has mainly been studied as a cream in cosmetics. KPV reduced gut inflammation in mouse models, taken up via the transporter PepT1. There are no injection studies in humans for either.1314151617

Which side effects are known?

There are no data for the blend. The three small BPC-157 human studies reported no treatment-related side effects. Thymosin beta-4 was well tolerated in a phase 1 trial into a vein. Solid long-term data are missing for all four. Reviews also warn about contamination from unregulated manufacturing.29311

Is the Klow Blend approved?

No. Neither the blend nor any of the four components is approved as a medicine (as of October 2026). ChEMBL lists BPC-157 with phase 1 as the highest phase; thymosin beta-4 reached phase 3 only as eye drops.204

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Blend
Several compounds ready-mixed in one vial. The proportions are fixed and cannot be adjusted individually.
BPC-157
Peptide of 15 amino acids, derived from a protective protein in gastric juice. Studied almost only in animals.
Cell migration
Movement of cells to the site of an injury, an early step of wound healing.
Colitis
Inflammation of the colon. In research often induced in mice to test compounds.
Collagen
Main structural protein of skin, tendons and connective tissue.
GHK-Cu
Tripeptide of glycine, histidine and lysine with bound copper. Found in the blood, the level falls with age.
KPV
Tripeptide of lysine, proline and valine, the end of the hormone alpha-MSH. Anti-inflammatory in mouse models.
Lyophilisate
Freeze-dried powder. Without water a peptide keeps much longer.
PepT1
Transporter in the gut wall that takes small peptides into cells. In gut inflammation it is produced more in the colon.
Preclinical
Studied in cells or animals, not yet in humans.
Subcutaneous
Into the fat layer just under the skin.
Systematic review
Overview that searches and rates all studies on a question by fixed rules.
TB-500
Peptide derived from thymosin beta-4. Thymosin beta-4 binds actin and plays a role in cell migration and repair.
Trial phases
Phase 1 tests tolerability in a few people, phase 2 looks for the dose, phase 3 confirms benefit and safety in thousands. After that, approval can be requested.

Evidence

Sources

Show all 20 sourcesHide sources 16 Studies2 Trial registry2 Database checked 26 Oct 2026

Studies

  1. BPC-157, TB-500 and both combined in tendon healing (rat)

    Biçer et al., Joint Diseases and Related Surgery, 2026

    DOI 10.52312/jdrs.2026.2951 PMID 42542926
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Systematic review of all human studies on BPC-157

    Poolton et al., Acta Orthopaedica Belgica, 2026

    DOI 10.52628/92.3.15837 PMID 42885452
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Systematic review of BPC-157 in orthopaedic sports medicine

    Vasireddi et al., HSS Journal, 2025

    DOI 10.1177/15563316251355551 PMID 40756949
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Literature and patent review of BPC-157

    Józwiak et al., Pharmaceuticals, 2025

    DOI 10.3390/ph18020185 PMID 40005999
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Review of BPC-157 in tendon, ligament and muscle

    Gwyer et al., Cell and Tissue Research, 2019

    DOI 10.1007/s00441-019-03016-8 PMID 30915550
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Randomised trial of GHK-Cu gel in diabetic foot ulcers

    Mulder et al., Wound Repair and Regeneration, 1994

    DOI 10.1046/j.1524-475X.1994.20406.x PMID 17147644
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. Thymosin beta-4 accelerates wound healing (rat)

    Malinda et al., Journal of Investigative Dermatology, 1999

    DOI 10.1046/j.1523-1747.1999.00708.x PMID 10469335
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  8. Thymosin beta-4 and cardiac repair (mouse)

    Bock-Marquette et al., Nature, 2004

    DOI 10.1038/nature03000 PMID 15565145
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  9. Phase 1 trial of intravenous thymosin beta-4 in healthy adults

    Ruff et al., Annals of the New York Academy of Sciences, 2010

    DOI 10.1111/j.1749-6632.2010.05474.x PMID 20536472
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  10. Review of the structure and function of thymosin beta-4

    Crockford et al., Annals of the New York Academy of Sciences, 2010

    DOI 10.1111/j.1749-6632.2010.05492.x PMID 20536467
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  11. Review of safety and efficacy of peptides in sports medicine

    Mendias & Awan, Sports Medicine, 2026

    DOI 10.1007/s40279-026-02437-0 PMID 41966639
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  12. Review of regeneration and gene data of GHK-Cu

    Pickart & Margolina, International Journal of Molecular Sciences, 2018

    DOI 10.3390/ijms19071987 PMID 29986520
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  13. Review of GHK in skin regeneration

    Pickart et al., BioMed Research International, 2015

    DOI 10.1155/2015/648108 PMID 26236730
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  14. Review of GHK and tissue remodelling

    Pickart, Journal of Biomaterials Science, Polymer Edition, 2008

    DOI 10.1163/156856208784909435 PMID 18644225
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  15. PepT1-mediated KPV uptake reduces intestinal inflammation (mouse)

    Dalmasso et al., Gastroenterology, 2008

    DOI 10.1053/j.gastro.2007.10.026 PMID 18061177
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  16. KPV in two mouse models of inflammatory bowel disease

    Kannengiesser et al., Inflammatory Bowel Diseases, 2008

    DOI 10.1002/ibd.20334 PMID 18092346
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials on the components on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2
  2. Registry search for the blend (0 results)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. PubMed search for the blend (0 results)

    PubMed, U.S. National Library of Medicine

    Checked 26 Oct 2026 via PubMed E-utilities
  2. BPC-157 and thymosin beta-4 in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL4297358, CHEMBL4594314)

    Checked 26 Oct 2026 via ChEMBL

In the shop

Klow Blend in the catalog

Sizes, prices and shipping times are on the product page.

To the product